NCT05237921: CEDI

Adherence to Exercise and Dietary Intervention in Cancer Patients

Completed NA Last updated 19 March 2024

What this trial tests

NA trial testing Combined Exercise and Dietary Intervention (CEDI) in Adherence in 50 participants. Completed in 30 June 2022.

Timeline

15 June 2018

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Hospital Beatriz Ângelo
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	50
Start date	15 June 2018
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across Portugal

Drugs / interventions tested

• Combined Exercise and Dietary Intervention (CEDI)
• Standard Care — full drug profile →

Conditions studied

• Adherence — all drugs for Adherence →
• Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →

Sponsor

Hospital Beatriz Ângelo

Who can join

Adults 18 to 80, any sex, with Adherence or Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intervention programs in cancer patients have been proposed with the aim of improving outcome. Bearing in mind that compliance is a limiting factor to the benefit provided from exercise and diet, assessing adherence to these interventions is paramount before pursuing further studies. Therefore the purpose of this study was to study the adherence of gastrointestinal cancer patients to a Combined Exercise and Dietary Intervention (CEDI) during neo-adjuvant chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Adherence to combined exercise and dietary intervention in patients with gastrointestinal cancer undergoing neo-adjuvant therapy: an open-label, pilot, randomized controlled trial.
   Velho SDF, Moço S, Capitão C, Branco M, et al · · 2022 · DOI 10.21203/rs.3.rs-1605755/v1